Fulranumab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Fulranumab
- amg 403
- AMG 403
- AMG-403
- amg403
- AMG403
- fulranumab
- Fulranumab
- fulranumab [INN]
- FULRANUMAB [USAN]
- Fulranumab [WHO-DD]
- Fulranumab 1 mg
- Fulranumab 3 mg
- fulranumab inn
- fulranumab usan
- fulranumab who dd
- immunoglobulin g2 anti human nerve growth factor human monoclonal 4d4 heavy chain disulfide with human monoclonal 4d4 light chain dimer
- IMMUNOGLOBULIN G2, ANTI-(HUMAN NERVE GROWTH FACTOR) (HUMAN MONOCLONAL 4D4 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL 4D4 LIGHT CHAIN, DIMER
- jnj 42160443
- JNJ 42160443
- JNJ-42160443
- JNJ-42160443 (1 mg)
- JNJ-42160443 (10 mg)
- JNJ-42160443 (3 mg)
- JNJ-42160443 1 mg
- JNJ-42160443 10 mg
And 1 more, listed on the interactive page.
- CAS registry numbers
- 902141-80-4
- ChEMBL ID
- CHEMBL1743023
- FDA ingredient codes (UNII)
- 0E986JU40I
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fulranumab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Binding
- Action type
- Binding
- Target
- NGF
- Gene symbol
- NGF
- Median affinity
- 11.4
- Affinity units
- pKd
- Primary target
- Yes
- Mechanism
- Beta-nerve growth factor inhibitor
- Action type
- Inhibitor
- Target
- Beta-nerve growth factor
- Protein identifier
- P01138
Open Targets mechanisms
- Mechanism
- Beta-nerve growth factor inhibitor
- Action type
- Inhibitor
- Target
- Beta-nerve growth factor
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Diabetic Neuropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000783
- Subject identifier
- D003929
- Condition
- Low Back Pain
- Highest recorded phase
- 2
- Condition identifier
- HP:0003419
- Subject identifier
- D017116
- Condition
- Chronic Pain
- Highest recorded phase
- 1
- Condition identifier
- HP:0012532
- Subject identifier
- D059350
- Condition
- Osteoarthritis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005178
- Subject identifier
- D010003
- Condition identifier
- EFO_0801084
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000783
- Highest recorded phase
- 2
- Condition identifier
- HP_0002829
- Highest recorded phase
- 3
- Condition identifier
- HP_0003418
- Highest recorded phase
- 3
- Condition identifier
- HP_0003419
- Highest recorded phase
- 2
- Condition identifier
- HP_0012531
- Highest recorded phase
- 3
- Condition identifier
- HP_0012532
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005416
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0041052
- Highest recorded phase
- 2
- NCT00929188
- NCT00973024
- NCT00993018
- NCT02289716
- NCT02318407
- NCT02348879
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Organism
- Homo sapiens
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Organism
- Homo sapiens
- Sequence
- AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (25)
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
- A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
- A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers
- A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
- A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
- A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
- A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
- A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
- A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
- A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain
- A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject
- A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
- Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
- GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
- Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
In development for (2)
- Diabetic neuropathy Phase 2
- Osteoarthritis Phase 3
Targets (1)
- NGF Beta-nerve growth factor inhibitor